Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-13-000378
Filing Date
2013-05-30
Accepted
2013-05-29 19:22:15
Documents
10
Period of Report
2012-11-30

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 11.30.12 naprodis10q113012.htm 10-Q 371870
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 11060
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 10153
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32.htm EX-32 6473
  Complete submission text file 0001127855-13-000378.txt   3741325

Data Files

Seq Description Document Type Size
5 napr-20121130_cal.xml EX-101.CAL 19698
6 napr-20121130_def.xml EX-101.DEF 21992
7 napr-20121130.xml EX-101.INS 765677
8 napr-20121130_lab.xml EX-101.LAB 93492
9 napr-20121130_pre.xml EX-101.PRE 93876
10 napr-20121130.xsd EX-101.SCH 27666
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 13879583
SIC: 2834 Pharmaceutical Preparations